Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics
AUTL Price/Volume Stats
| Current price | $2.03 | 52-week high | $6.93 |
| Prev. close | $2.04 | 52-week low | $1.87 |
| Day low | $2.01 | Volume | 1,129,079 |
| Day high | $2.15 | Avg. volume | 1,157,206 |
| 50-day MA | $2.34 | Dividend yield | N/A |
| 200-day MA | $3.53 | Market Cap | 540.17M |
AUTL Stock Price Chart Interactive Chart >
Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio
Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.
AUTL Price Returns
| 1-mo | -8.56% |
| 3-mo | -27.50% |
| 6-mo | -48.74% |
| 1-year | N/A |
| 3-year | -53.01% |
| 5-year | -80.74% |
| YTD | -13.62% |
| 2024 | -63.51% |
| 2023 | 238.95% |
| 2022 | -63.39% |
| 2021 | -41.95% |
| 2020 | -32.27% |
Loading social stream, please wait...